Lead identification of conformationally restricted β-lactam type combretastatin analogues: Synthesis, antiproliferative activity and tubulin targeting effects

European Journal of Medicinal Chemistry

Volumn 45, Issue 12, 2010, Pages 5752-5766

  Carr, Miriam ^a   Greene, Lisa M ^a   Knox, Andrew J S ^a   Lloyd, David G ^a   Zisterer, Daniela M ^a   Meegan, Mary J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Lactam; 2 Azetidinone; Combretastatin A 4 analogues; Cytotoxicity; Structure activity; Tubulin

Indexed keywords

1 (3,4,5 TRIMETHOXYPHENYL) 4 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; 1 [(3 TERT BUTYLDIMETHYLSILANYLOXY) 4 METHOXYPHENYL] 3 METHYL 4 (3,4,5 TRIMETHOXY PHENYL)AZETIDIN 2 ONE; 1 [(3 TERT BUTYLDIMETHYLSILANYLOXY) 4 METHOXYPHENYL] 3,3 DIMETHYL 4 (3,4,5 TRIMETHOXY PHENYL)AZETIDIN 2 ONE; 1 [(3 TERT BUTYLDIMETHYLSILANYLOXY) 4 METHOXYPHENYL] 4 (3,4,5 TRIMETHOXY PHENYL)AZETIDIN 2 ONE; 1,4 DIARYL 2 AZETIDINONE; 4 (2,3,4 TRIMETHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; 4 (2,4,5 TRIMETHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; 4 (3 HYDROXY 4 METHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; 4 (3 HYDROXY 4 METHOXYPHENYL) 3 METHYLE 1 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; 4 (3,4 DIMETHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; 4 (3,4 DIMETHOXYPHENYL) 3 METHYL 1 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; 4 (3,4 DIMETHOXYPHENYL) 3,3 DIMETHYL 1 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; 4 (4 FLUOROPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; 4 (4 METHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; 4 (4 METHOXYPHENYL) 3 METHYL 1 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; 4 (4 METHOXYPHENYL) 3,3 DIMETHYL 1 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; 4 (7 METHOXYNAPHTHALEN 2 YL) 1 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; 4 [(3 TERT BUTYLDIMETHYLSILANYLOXY) 4 METHOXYPHENYL] 3 METHYL 1 (3,4,5 TRIMETHOXY PHENYL)AZETIDIN 2 ONE; 4 [(3 TERT BUTYLDIMETHYLSILANYLOXY) 4 METHOXYPHENYL] 3,3 DIMETHYL 1 (3,4,5 TRIMETHOXY PHENYL)AZETIDIN 2 ONE; 4 [3 (TERT BUTYLDIMETHYLSILANYLOXY) 4 METHOXYPHENYL] 1 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; 4 THIOPHEN 2 YL 1 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; ANTIMITOTIC AGENT; BETA LACTAM; COMBRETASTATIN A4; ETHYLENE; LEAD; METHYL GROUP; STILBENE; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONCENTRATION (PARAMETERS); CONFORMATION; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; POLYMERIZATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA-LACTAMS; CATTLE; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; STEREOISOMERISM; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN;

EID: 78649326841     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.09.033     Document Type: Article

References (49)

1. K.H. Downing, and E. Nogales Tubulin and microtubule structure Curr. Opin. Cell Biol. 10 1998 16 22
2. M.A. Jordan Mechanism of action of antitumor drugs that interact with microtubules and tubulin Curr. Med. Chem. Anticancer Agents 2 2002 1 17
3. M.A. Jordan, and L. Wilson Microtubules as a target for anticancer drugs Nat. Rev. Cancer 4 2004 253 265
4. J.A. Hadfield, S. Ducki, N. Hirst, and A.T. McGown Tubulin and microtubules as targets for anticancer drugs Prog. Cell Cycle Res. 5 2003 309 325
5. R.L. Margolis, C.T. Rauch, and L. Wilson Mechanism of colchicine-dimer addition to microtubule ends: implications for the microtubule polymerization mechanism Biochemistry 19 1980 5550 5557
6. B. Bhattacharyya, D. Panda, S. Gupta, and M. Banerjee Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin Med. Res. Rev. 28 2008 155 183
7. G.R. Pettit, S.B. Singh, E. Hamel, C.M. Lin, D.S. Alberts, and D. Garcia-Kendall Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 Experientia 45 1989 209 211
8. J.W. Lippert 3rd Vascular disrupting agents Bioorg. Med. Chem. 15 2007 605 615
9. P. Hinnen, and F.A. Eskens Vascular disrupting agents in clinical development Br. J. Cancer 96 2007 1159 1165
10. K.G. Pinney, C. Jelinek, K. Edvardsen, D.J. Chaplin, and G.R. Pettit The discovery and development of combretastatins G.M. Cragg, D.G.I. Kingston, D.J. Newman, Anticancer Agents from Natural Products 2005 Taylor & Francis Boca Raton, FL 23 46
11. A. Cirla, and J. Mann Combretastatins: from natural products to drug discovery Nat. Prod. Rep. 20 2003 558 564
12. G.R. Pettit, C. Temple Jr., V.L. Narayanan, R. Varma, M.J. Simpson, M.R. Boyd, G.A. Rener, and N. Bansal Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs Anticancer Drug Des. 10 1995 299 309
13. http://www.clinicaltrials.gov/ct/gui/show/NCT00060242
14. M.M. Cooney, J. Ortiz, R.M. Bukowski, and S.C. Remick Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds Curr. Oncol. Rep. 7 2005 90 95
15. S.L. Young, and D.J. Chaplin Combretastatin A4 phosphate: background and current clinical status Expert Opin. Investig. Drugs 13 2004 1171 1182
16. G.R. Pettit, M.R. Rhodes, D.L. Herald, E. Hamel, J.M. Schmidt, and R.K. Pettit Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41 J. Med. Chem. 48 2005 4087 4099
17. K. Ohsumi, T. Hatanaka, K. Fujita, R. Nakagawa, Y. Fukuda, Y. Nihei, Y. Suga, Y. Morinaga, Y. Akiyama, and T. Tsuji Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues Bioorg. Med. Chem. Lett. 8 1998 3153 3158
18. M. Cushman, D. Nagarathnam, D. Gopal, A.K. Chakraborti, C.M. Lin, and E. Hamel Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization J. Med. Chem. 34 1991 2579 2588
19. G.C. Tron, T. Pirali, G. Sorba, F. Pagliai, S. Busacca, and A.A. Genazzani Medicinal chemistry of combretastatin A4: present and future directions J. Med. Chem. 49 2006 3033 3044
20. N.H. Nam Combretastatin A-4 analogues as antimitotic antitumor agents Curr. Med. Chem. 10 2003 1697 1722
21. H.P. Hsieh, J.P. Liou, and N. Mahindroo Pharmaceutical design of antimitotic agents based on combretastatins Curr. Pharm. Des. 11 2005 1655 1677
22. M. Cushman, D. Nagarathnam, D. Gopal, H.M. He, C.M. Lin, and E. Hamel Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5- trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents J. Med. Chem. 35 1992 2293 2306
23. K. Ohsumi, R. Nakagawa, Y. Fukuda, T. Hatanaka, Y. Morinaga, Y. Nihei, K. Ohishi, Y. Suga, Y. Akiyama, and T. Tsuji Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships J. Med. Chem. 41 1998 3022 3032
24. T. Brown, H. Holt Jr., and M. Lee Series: topics in heterocyclic chemistry M.E. Lee, Heterocyclic Antitumor Antibiotics vol. 2 2006 Springer Berlin/Heidelberg 1 51
25. L. Wang, K.W. Woods, Q. Li, K.J. Barr, R.W. McCroskey, S.M. Hannick, L. Gherke, R.B. Credo, Y.H. Hui, K. Marsh, R. Warner, J.Y. Lee, N. Zielinski-Mozng, D. Frost, S.H. Rosenberg, and H.L. Sham Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation J. Med. Chem. 45 2002 1697 1711
26. R. Shirai, H. Takayama, A. Nishikawa, Y. Koiso, and Y. Hashimoto Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells Bioorg. Med. Chem. Lett. 8 1998 1997 2000
27. G.C. Tron, F. Pagliai, E. Del Grosso, A.A. Genazzani, and G. Sorba Synthesis and cytotoxic evaluation of combretafurazans J. Med. Chem. 48 2005 3260 3268
28. O.G. Ganina, E. Daras, V. Bourgarel-Rey, V. Peyrot, A.N. Andresyuk, J.P. Finet, A.Y. Fedorov, I.P. Beletskaya, and S. Combes Synthesis and biological evaluation of polymethoxylated 4-heteroarylcoumarins as tubulin assembly inhibitor Bioorg. Med. Chem. 16 2008 8806 8812
29. J.P. Liou, Y.L. Chang, F.M. Kuo, C.W. Chang, H.Y. Tseng, C.C. Wang, Y.N. Yang, J.Y. Chang, S.J. Lee, and H.P. Hsieh Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents J. Med. Chem. 47 2004 4247 4257
30. I. Banik, F.F. Becker, and B.K. Banik Stereoselective synthesis of beta-lactams with polyaromatic imines: entry to new and novel anticancer agents J. Med. Chem. 46 2003 12 15
31. L. Sun, N.I. Vasilevich, J.A. Fuselier, S.J. Hocart, and D.H. Coy Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design Bioorg. Med. Chem. Lett. 14 2004 2041 2046
32. M.J. Meegan, M. Carr, A.J. Knox, D.M. Zisterer, and D.G. Lloyd Beta-lactam type molecular scaffolds for antiproliferative activity: synthesis and cytotoxic effects in breast cancer cells J. Enzyme Inhib. Med. Chem. 23 2008 668 685
33. C.C. Palomo, P. Fernando, Ana Arrieta, Jose M. Odriozola, Mikel Oiarbide, and Jesus M. Ontoria The Reformatskii type reaction of Gilman and Speeter in the preparation of valuable β-lactams in carbapenem synthesis: scope and synthetic utility J. Org. Chem. 54 1989 5736 5745
34. A. Gaudemer Determination of configurations by NMR spectroscopy H.B. Kagan, Stereochemistry: Fundamentals and Methods Determination of Configurations by Spectroscopic Methods vol. 1 1977 Georg Thieme Publishers Stuttgart 87
35. S.B. Rosenblum, T. Huynh, A. Afonso, H.R. Davis Jr., N. Yumibe, J.W. Clader, and D.A. Burnett Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4- fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption J. Med. Chem. 41 1998 973 980
36. J.W. Clader The discovery of ezetimibe: a view from outside the receptor J. Med. Chem. 47 2004 1 9
37. B.L. Flynn, G.P. Flynn, E. Hamel, and M.K. Jung The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4 Bioorg. Med. Chem. Lett. 11 2001 2341 2343
38. G. De Martino, G. La Regina, A. Coluccia, M.C. Edler, M.C. Barbera, A. Brancale, E. Wilcox, E. Hamel, M. Artico, and R. Silvestri Arylthioindoles, potent inhibitors of tubulin polymerization J. Med. Chem. 47 2004 6120 6123
39. J.M. Bidlack, and R.A. Lockshin Evolution of LDH isozymes during programmed cell death Comp. Biochem. Physiol., B 55 1976 161 166
40. W.t.S. C-QSAR; Biobyte Corp., Suite 204, Claremont, CA.
41. M. Cushman, H.M. He, C.M. Lin, and E. Hamel Synthesis and evaluation of a series of benzylaniline hydrochlorides as potential cytotoxic and antimitotic agents acting by inhibition of tubulin polymerization J. Med. Chem. 36 1993 2817 2821
42. R.B. Ravelli, B. Gigant, P.A. Curmi, I. Jourdain, S. Lachkar, A. Sobel, and M. Knossow Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain Nature 428 2004 198 202
43. T. Schulz-Gasch, and M. Stahl Binding site characteristics in structure-based virtual screening: evaluation of current docking tools J. Mol. Model. 9 2003 47 57
44. M. Feher, and C.I. Williams Effect of input differences on the results of docking calculations J. Chem. Inf. Model. 2009
45. T. Takagi, M. Amano, and M. Tomimoto Novel method for the evaluation of 3D conformation generators J. Chem. Inf. Model. 49 2009 1377 1388
46. I. Barrett, M. Carr, N. O'Boyle, L.M. Greene, A.J. Knox, D.G. Lloyd, D.M. Zisterer, and M.J. Meegan Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects J. Enzyme Inhib. Med. Chem. 25 2010 180 194
47. MOEv2008.10, developed and distributed by Chemical Computing Group http://www.chemcomp.com
48. F. Lara-Ochoa, and G. Espinosa-Perez A new synthesis of combretastatins A-4 and AVE-8062A Tetrahedron Lett 48 2007 7007 7010
49. R. Shirai, H. Nobuatsu, T. Okabe, K. Koiso, S. Iwasaki, Preparation of azacombretastatin compounds as antitumor agents; Taisho Pharma Co Ltd; Jpn. Kokai Tokkyo Koho (1996), JP 08067656 A 19960312.